中文摘要：

目的探讨雷利度胺联合地塞米松对T淋巴瘤细胞增殖与凋亡的影响。方法预实验后选取雷利度胺（40、80、120、160、200、400、600mg／L）、地塞米松（50、100、150、200、250mg／L）及两药联用处理人T淋巴瘤Jurkat细胞24、48、72h；M1Tr法测试细胞毒性，流式细胞术检测细胞周期，光镜、荧光显微镜进行形态学观察，AnnexinV染色检测凋亡率。结果雷利度胺和地塞米松均以浓度和时间依赖性方式抑制Jurkat细胞生长，诱导Jurkat细胞凋亡。雷利度胺和地塞米松联合处理组的Jurkat细胞增殖受抑率显著高于单用雷利度胺组（P〈0．05）和单用地塞米松处理组（P〈0．05）。结论雷利度胺和地塞米松联合具有协同抗T细胞淋巴瘤作用，本研究为雷利度胺和地塞米松临床联合应用于T细胞淋巴瘤提供了理论基础。

英文摘要：

Objective To study the effect of combination of Lenalidomide and Dexamethasone （DEX） on the T lymphoma cells growth and apoptosis. Methods After the preliminary experiment, Lenalidomide （40, 80, 120, 160, 200, 400, 600 mg/L） and Dexamethasone （50, 100, 150, 200, 250 rag/L）, and the combination of these two drugs were used to treat Ju- rkat lymphoma cells for 24,48 or 72 hours. MTT was used to evaluate the eytotoxic effects. Flow cytometry was used to detect cell cycle. Cellular morphologic changes of apoptotic cell nucleus were observed using the Hoechst 33258 stain- ing. The percentage of apoptosis cells was detected by flow cytometry using Annexin ~-FITC/PI Apoptosis assay. Re- suits Both Lenalidomide and Dexamethasone could inhibit the cells proliferation and induce the apoptosis of Jurkat cells in a dose and time dependent manner. There was a significant increase of the cell inhibitory rate after exposure to combination of Lenalidomide and Dexamethasone compared to Lenalidomide alone （/9 〈 0.05） or Dexamethasone alone （P 〈 0.05）. Conclusion Combination of Lenalidomide and Dexamethasone has synergistic activity in inhibition of T lymphoma cells. This study, therefore, provides the framework for clinical evaluation of Lenalidomide combined with Dexamethasone to improve patients＂ outcome in T lymphoma.